Navigation Links
principle in Medical Technology

Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly

... Company (NYSE: LLY ) today announced that the companies have agreed in principle to the terms of a joint supply agreement for an exenatide once weekly pen ... Once Weekly Pen Supply Agreement Amylin and Lilly have agreed in principle to cooperate in the development, manufacturing and marketing of exenatide ...

Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer

... who have received no more than two prior cytotoxic cancer therapies. The principle Investigator of the trial is Dr. Charles Shapiro, Director of Breast ... listed investigators: Institution Site principle Investigator Breastlink Medical Group, Long Beach, California ...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... with the poor prognosis of patients with B. cepacia infection, makes the treatment of these patients exceedingly complex. Tobramycin is in principle an effective antibiotic. The drug is however rather ineffective due to the impermeability of B. cepacia's cell envelope. In addition, B. cepacia - ...

USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic

... competitive award program designed to assist translation of novel anticancer therapeutics to the clinic. The goal of the program is to show proof of principle that a new molecule is a viable candidate for expanded clinical evaluation. As a RAID award recipient, Dr. Epstein will receive access to drug ...

Cardiovascular Fitness Not Affected by Cancer Treatment

... affiliation with MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health ...

Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program

... from person-to-person. Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and principle Investigator of the program, added, "We have been very pleased with the results of our development effort. The products have shown to be remarkably ...

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

... duration of six weeks. This six week randomized, double blind placebo controlled study will be performed in three locations in Cape Town. The principle investigators of the study will be renowned South African Endocrinologists. "We are pleased to begin this study of ORMD-0801 on Type 2 ...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

... that do not respond to therapy or who experience recurrence," said Ranjana Advani, MD, Associate Professor, Stanford University Medical Center and principle investigator of the Phase 1 clinical trial. "A drug that could not only have an impact on this patient group, but also be delivered orally would ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... year. "The relapse of colorectal cancer patients with liver metastases still represents an area with very high medical need" said the trial's principle investigator, Professor Peter Neuhaus, from the Charite University Hospital in Berlin, Germany. "Recent intensification of chemotherapeutic regimens ...

Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects

... IN Apomorphine formulation (3.5 mg dose), compared with a commercial subcutaneous (SC) injection (2 mg dose), were demonstrated in a Phase I proof of principle study in 12 healthy volunteers. IN Apomorphine was well and reproducibly absorbed via the nasal route with therapeutically relevant plasma ...

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

... at the following clinical sites under the directorship of the listed investigators: Institution Site principle Investigator California Cancer Care Inc., Greenbrae/San Mateo, California Dr. Peter Eisenberg Columbia Presbyterian ...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

... of lesions as effectively as the leading oral systemic drugs but without safety or toxicity concerns. The new data provide the first proof of principle that a topical agent can attain equivalent efficacy rates to oral systemic drugs, according to the NanoBio scientists. Topical treatments are widely ...

Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation

... Alzheimer's, and Autism. The PSD makes use of a property called the Photoconductive Stimulation Effect (PSE). This novel device is based on the PSE principle that states when visible light strikes silicon in combination with a specific current, a local field potential (LFP) is generated. This LFP can be ...

Study Suggests a Possible Way to Offset Chemobrain Memory Loss

... collaborated on the study. The study was funded as part of a $275,000 grant over three years from the U.S. Department of Defense. Abraham is principle investigator on the studies. This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com . ...

n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure

... Pfizer About heart failure Heart failure is not a single disease, but instead is the end result of several cardiac disease processes, and is the principle complication of virtually all forms of heart disease. In Europe and the United States altogether, around 10 million people have been diagnosed with ...

Oregon Tourism Commission Unveils New Online Customer Service Training Program

... adage that it costs more to attract a first-time guest than a repeat customer," said Todd Davidson, Travel Oregon's CEO. "The heart and soul of this principle resides in that first-time customer's experience and how likely they will be to return as a result. The Oregon Q Care program raises the bar on the ...

Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies

... Design Symposium, sponsored by the New York Academy of Sciences. Dr. Paul H. Pevsner, NYU School of Medicine (Department of Pharmacology) and principle investigator for the research studies, commented: "PCT is critical to our work. This novel, cutting-edge technology consistently gives us rapid and ...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

... blocking agents and a potentially promising class of anti-HIV compounds," said, Dr. June who is the senior author of the study. "These proof of principle data, together with experience from individuals that carry a natural mutation in their CCR5 gene suggest that permanent 'knock-out' of the of CCR5 ...

VA Statement on Smoking Cessation Research Program

... the U.S. Surgeon General's office has established. VA is committed to the ethical treatment of all who participate in our research studies, to the principle of informed consent, and to treating veterans participating in our research programs with the highest quality and most advanced health care ....

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose. "These positive data validate a key principle underlying the Cotara program, confirming its ability to specifically concentrate in and deliver a high radiation dose to brain tumors," said Steven ...

Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca

... with coronary artery disease. The SATURN study is chaired by Steve Nissen, M.D., with Steve Nichols, M.D. from the Cleveland Clinic Core Lab as the principle investigator. Under this protocol, physicians enrolling patients may select the Volcano Revolution(R) IVUS catheters as their IVUS catheter of ....

Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments

... physicians' understanding of genetic assessments and the impact of such information on preventive health decision making. Titled "A Proof of principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment," the study begins this month and runs through September 2009. The ...

EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia

... of EVP-6124 on sensitive electrophysiology markers (the P50 auditory evoked response and mismatch negativity) in Schizophrenia patients. The principle investigator is Dr. Sheldon H. Preskorn and the study is being conducted at the Clinical Research Institute (CRI) in Wichita, Kansas. Dr. Preskorn is ...

Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights

... 2006, the Company recorded an expense of $5.3 million that provided for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense is net of insurance recovery of $18.0 million. At December 31, 2007, the revised estimated value of the ...

Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.

... step toward making a microbicide accessible to those who most need it. Ensuring access is an essential element of IPM's mission -- and a guiding principle throughout its development process. To that end, IPM has obtained royalty-free licenses for five antiretroviral compounds from pharmaceutical ...

CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids

... outer layer of the Company's proprietary coating, Polyzene(R)-F which enhances biocompatibility. "From the beginning, CeloNova has operated on the principle that our products would give first-rate clinical outcomes for patients and meet the real-world needs of physicians," said Thomas A. Gordy, President ...

Genta Incorporated Announces Third Quarter 2007 Financial Results

... 2006, the Company recorded an expense of $5.3 million that provides for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense was net of insurance recovery of $18.0 million. At September 30, 2007, the revised estimated value of the ...

St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory

... at St. Jude Children's Research Hospital have identified the cell that gives rise to the eye cancer retinoblastoma, disproving a long-standing principle of nerve growth and development. The finding suggests for the first time that it may one day be possible for scientists to induce fully developed ...

Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)

... will be Dr. Gabi Chiorean, Assistant Professor of Medicine from the Indiana University Cancer Center in Indianapolis, Indiana. Dr. Chiorean is the principle investigator on Threshold's Phase 2 glufosfamide trial in first-line pancreatic cancer patients, and she was present at ECCO to preside over the ...

Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products

... Alticor Inc.), after screening hundreds of plant extracts in the laboratory for their ability to reduce IL-1 production. "This study supports the principle of nutritional genetics," said Interleukin President and Chief Scientific Officer Dr. Kenneth Kornman. "In addition to highlighting the successful ...

CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue

... . About CellCyte Genetics CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products. For further information see: ...

Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference

... concern for active immunization of Alzheimer's disease patients. "We are pleased with our scientists' progress in establishing important proof of principle for this novel and proprietary vaccine technology, which is designed to make active immunization safe and practical for treating Alzheimer's ...

Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

... 2006, the Company recorded an expense of $5.3 million that provides for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense is net of insurance recovery of $18.0 million. At June 30, 2007, the revised estimated value of the common ...

Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine

... on the resulting vaccine-specific immune responses in rhesus macaques," summarized results of a research project lead by Michael A. Egan, Ph.D., a principle research scientist at Wyeth Vaccine Research. The scientific paper concluded: "These results indicate that in vivo electroporation appears safe and ...

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

... Medical Director of the Krembil Neuroscience Center and Head of the Spinal Program at the University Health Network of the University of Toronto and principle investigator in the study. Co-authors are Nicholas Theodore, MD, James Harrop, MD, Gilles Maurais, MD, Charles Kuntz, MD, Christopher Shaffrey, MD, ...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

... these problems by combining the immunomodulatory activity of the cytokine with the tumor specificity of a targeted antibody. In these proof of principle studies, VTA immunocytokines were created by combining type I interferon and interleukin 2 with 2aG4, an anti-phospholipid antibody similar to ...

Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine

... efficacy endpoints there were no statistically significant differences between the two dose groups. "The study results show an important and novel principle in the treatment of migraine with the positive outcome using an mGluR5 receptor modulator. The data offer the real prospect of development of a ...

Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases

... The drug is clearly working," said Kim Papp, M.D., Ph.D., Assistant Clinical Professor of Medicine at the University of Western Ontario, Canada and a principle investigator of the Phase II study. Adverse side effects in patients receiving CC-10004 were mild and well tolerated. Overall, the percentage of ...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

... Avtar Dhillon, Inovio's CEO, said, "This pioneering clinical study is providing compelling evidence of safety and tolerability as well as proof of principle for DNA delivery and expression using electroporation to deliver DNA into human subjects - without need of a viral or lipid vector. We look forward ...
Other Contents
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... Ebola cases in Dallas. But, mental health specialists say overblown ... President Barack Obama on Friday appointed an Ebola "czar" to ... two Dallas nurses who cared for a Liberian man who ... But the U.S. cases are miniscule in the context ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment ... Institutes for Research (AIR) finds that three out of four ... but 42 percent say they are not likely or only ... for coverage. , The AIR survey found wide gaps in ... calculate correctly how much they owe for a routine doctor’s ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 ... guidelines for health workers treating Ebola patients, now requiring full ... respirator at all times. The U.S. Centers for Disease ... two Dallas nurses contracted Ebola while caring for the first ... Eric Duncan. Nina Pham is currently being treated for her ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
Other TagsOther Tags